Eli Lilly and Company
Pharmaceutical company with gene therapy licensing deal with REGENXBIO
Every fact below is drawn from Via News's knowledge graph and linked to the source document it came from. Nothing here is unsourced. How we source →
Key metrics · each point sourced
Stated objectives
Expand access to obesity medicines to nearly 40 million Americans on government insurance programs
sourceReduce Medicare beneficiary out-of-pocket costs for Zepbound and orforglipron to maximum $50 per month
sourceAdvance one of the most innovative obesity pipelines
sourceInvest more than $50 billion in U.S. manufacturing to boost domestic production in key therapeutic areas
sourceOffer LillyDirect pricing for Emgality, Trulicity, and Mounjaro at 50-60% off current list prices
sourceContinue to offer insulin at no more than $35 per month out-of-pocket
sourceComplete regulatory submission for oral orforglipron
sourceObtain U.S. regulatory approval for Inluriyo in combination with abemaciclib for ESR1-mutated MBC
sourceAdvance LY4064809/STX-478 from Phase 1/2 to Phase 3 trial for PIK3CA-mutant HR+, HER2- advanced breast cancer
sourceDemonstrate overall survival benefit, progression-free survival, and time to chemotherapy improvements in EMBER-3 trial for ESR1-mutated breast cancer
source